Infliximab for Dolichoectatic Vertebrobasilar Aneurysms
This study is testing a medication called infliximab for people with a specific type of brain aneurysm called dolichoectatic vertebrobasilar (DVB) aneurysm. These aneurysms are often difficult to treat with surgery. Researchers believe that infliximab, which works by blocking a protein called Tumor Necrosis Factor-alpha (TNFα) involved in inflammation, might help reduce the size of these aneurysms. The study aims to see if infliximab can shrink the aneurysm volume over 12 months. You may be able to join if you are over 18 and have a DVB aneurysm that cannot be treated by other methods. You cannot have used other similar medications in the past year. The study plans to enroll 8 participants, but its current status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 8 participants. It is not specified if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, reduction in aneurysm volume, is measured at 12 months, indicating a follow-up period of at least one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Daniel L Cooke, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Reduction in aneurysm volume (ml)12 months
Our primary outcome for assessing the effectiveness of the infliximab treatment will be the reduction in aneurysm volume over the treatment course based on the 0 and 12 month MR scans. DVB aneurysm volume will be assessed by review of standardized 1.5 mm slices in the axial plane. The contour of the aneurysm using time-of-flight MR angiography sequences will generate a cross-sectional area at each slice level. The volume will be estimated by summing the imputed volume of each slice. Standard T1- and T2-weighted sequences will also be obtained, as well as iron-sensitive sequencing.